

Andreas Stallmach

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/5315917/publications.pdf>

Version: 2024-02-01

102
papers

4,036
citations

126907

33
h-index

128289

60
g-index

132
all docs

132
docs citations

132
times ranked

5508
citing authors

#	ARTICLE	IF	CITATIONS
1	Mobile primary healthcare for post-COVID patients in rural areas: a proof-of-concept study. <i>Infection</i> , 2023, 51, 337-345.	4.7	4
2	T Cell Response After SARS-CoV-2 Vaccination in Immunocompromised Patients with Inflammatory Bowel Disease. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 251-258.	1.3	37
3	Prospective, double-blind diagnostic multicentre study of confocal laser endomicroscopy for wheat sensitivity in patients with irritable bowel syndrome. <i>Gut</i> , 2022, 71, 1567-1576.	12.1	15
4	Comparison of fatigue, cognitive dysfunction and psychological disorders in post-COVID patients and patients after sepsis: is there a specific constellation?. <i>Infection</i> , 2022, 50, 661-669.	4.7	35
5	SARS-CoV-2 vaccination does not induce relapses of patients with inflammatory bowel disease. <i>Zeitschrift Fur Gastroenterologie</i> , 2022, 60, 77-80.	0.5	8
6	Detection of Liver Dysfunction Using a Wearable Electronic Nose System Based on Semiconductor Metal Oxide Sensors. <i>Biosensors</i> , 2022, 12, 70.	4.7	7
7	Clinical predictors for a complicated course of disease in an inception cohort of patients with ulcerative colitis: results from the prospective, observational EPICOL study. <i>International Journal of Colorectal Disease</i> , 2022, 37, 485-493.	2.2	6
8	ROS-sensitive Polymer Micelles for Selective Degradation in Primary Human Monocytes from Patients with Active IBD. <i>Macromolecular Bioscience</i> , 2022, 22, e2100482.	4.1	8
9	Transfer of Frozen Encapsulated multi-donor Stool filtrate for active ulcerative Colitis (FRESCO): study protocol for a prospective, multicenter, double-blind, randomized, controlled trial. <i>Trials</i> , 2022, 23, 173.	1.6	7
10	Nondestructive molecular imaging by Raman spectroscopy vs. marker detection by MALDI IMS for an early diagnosis of HCC. <i>Analyst</i> , 2021, 146, 1239-1252.	3.5	8
11	Appendectomy in childhood – did it save my sibling from getting ulcerative colitis?. <i>International Journal of Colorectal Disease</i> , 2021, 36, 623-624.	2.2	3
12	Morbus Crohn. , 2021, , 234-247.		0
13	The COVID-19 Pandemic: Fears and Overprotection in Pediatric Patients with Inflammatory Bowel Disease and Their Families. <i>Pediatric Gastroenterology, Hepatology and Nutrition</i> , 2021, 24, 65.	1.2	10
14	Balance between macrophage migration inhibitory factor and sCD74 predicts outcome in patients with acute decompensation of cirrhosis. <i>JHEP Reports</i> , 2021, 3, 100221.	4.9	12
15	Greenspace in Childhood: A New Avenue to Prevent Inflammatory Bowel Disease?. <i>American Journal of Gastroenterology</i> , 2021, 116, 1964-1965.	0.4	2
16	SARS-CoV-2 Vaccination in Patients With Inflammatory Bowel Disease – Fear and Desire. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 1858-1861.	1.9	17
17	The impact of specific cytokine directed treatment on severe COVID-19. <i>Leukemia</i> , 2021, 35, 3613-3615.	7.2	3
18	Acceptance of SARS-CoV-2 vaccines by liver transplant recipients and candidates. <i>Zeitschrift Fur Gastroenterologie</i> , 2021, 59, 1288-1296.	0.5	3

#	ARTICLE	IF	CITATIONS
19	Clinical characteristics and outcome of patients with enterococcal liver abscess. <i>Scientific Reports</i> , 2021, 11, 22265.	3.3	8
20	Transcriptional Suppression of the NLRP3 Inflammasome and Cytokine Release in Primary Macrophages by Low-Dose Anthracyclines. <i>Cells</i> , 2020, 9, 79.	4.1	7
21	Infliximab against severe COVID-19-induced cytokine storm syndrome with organ failure—a cautionary case series. <i>Critical Care</i> , 2020, 24, 444.	5.8	71
22	Thumb sucking or nail biting in childhood and adolescence is associated with an increased risk of Crohn's disease: results from a large case-control study. <i>Scandinavian Journal of Gastroenterology</i> , 2020, 55, 1028-1034.	1.5	4
23	Towards an Interpretable Classifier for Characterization of Endoscopic Mayo Scores in Ulcerative Colitis Using Raman Spectroscopy. <i>Analytical Chemistry</i> , 2020, 92, 13776-13784.	6.5	27
24	Inflammatory Bowel Disease in the COVID-19 Pandemic: the Patients' Perspective. <i>Journal of Crohn's and Colitis</i> , 2020, 14, 1702-1708.	1.3	67
25	Between fear and courage: Attitudes, beliefs, and behavior of liver transplantation recipients and waiting list candidates during the COVID-19 pandemic. <i>American Journal of Transplantation</i> , 2020, 20, 3042-3050.	4.7	44
26	Influence of Core Cross-Linking and Shell Composition of Polymeric Micelles on Immune Response and Their Interaction with Human Monocytes. <i>Biomacromolecules</i> , 2020, 21, 1393-1406.	5.4	13
27	Mucosal-Associated Invariant T Cells Redistribute to the Peritoneal Cavity During Spontaneous Bacterial Peritonitis and Contribute to Peritoneal Inflammation. <i>Cellular and Molecular Gastroenterology and Hepatology</i> , 2020, 9, 661-677.	4.5	24
28	Fecal Microbiota Transfer. <i>Deutsches A&#x0308;rztblatt International</i> , 2020, 117, 31-38.	0.9	15
29	Letter: SARS-CoV-2-induced gastrointestinal inflammation. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1748-1749.	3.7	8
30	Predictive parameters for the clinical course of Crohn's disease: development of a simple and reliable risk model. <i>International Journal of Colorectal Disease</i> , 2019, 34, 1653-1660.	2.2	7
31	Long-term Multidonor Faecal Microbiota Transfer by Oral Capsules for Active Ulcerative Colitis. <i>Journal of Crohn's and Colitis</i> , 2019, 13, 1480-1481.	1.3	15
32	Sustained Clinical Remission With Vedolizumab in Patients With Moderate-to-Severe Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1028-1035.	1.9	22
33	Hepatitis E is a frequent cause of severe acute liver injury—a tertiary referral center experience. <i>Zeitschrift Fur Gastroenterologie</i> , 2019, 57, .	0.5	0
34	Morbus Crohn. , 2019, , 196-208.		0
35	Letter: predicting azathioprine-associated pancreatitis in IBD—phenotype or genotype?. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 47, 1042-1043.	3.7	2
36	Microbial Spectrum of Intra-Abdominal Abscesses in Perforating Crohn's Disease: Results from a Prospective German Registry. <i>Journal of Crohn's and Colitis</i> , 2018, 12, 695-701.	1.3	13

#	ARTICLE	IF	CITATIONS
37	Inflammatory bowel disease and Clostridium difficile infection: contrasting views of international clinical professionals. Zeitschrift Fur Gastroenterologie, 2018, 56, 731-737.	0.5	4
38	Vedolizumab in the treatment of chronic, antibioticâ€dependent or refractory pouchitis. Alimentary Pharmacology and Therapeutics, 2018, 47, 581-587.	3.7	64
39	Effective use of ustekinumab for prepouch ileitis without improvement of concomitant pouchitis. Techniques in Coloproctology, 2018, 22, 251-252.	1.8	6
40	Morbus Crohn. , 2018, , 361-372.		0
41	Blood group B is associated with azathioprine-induced acute pancreatitis in patients with IBD. Gut, 2017, 66, 1531-1532.	12.1	11
42	Azathioprine allows glucocorticoid withdrawal â€ post hoc results of a prospective study in patients with inflammatory bowel diseases. Zeitschrift Fur Gastroenterologie, 2017, 55, 461-465.	0.5	1
43	Consensus report: faecal microbiota transfer â€ clinical applications and procedures. Alimentary Pharmacology and Therapeutics, 2017, 45, 222-239.	3.7	95
44	Treatment of refractory ascites with an automated lowâ€flow ascites pump in patients with cirrhosis. Alimentary Pharmacology and Therapeutics, 2017, 46, 981-991.	3.7	46
45	Genetic variants of TRAF6 modulate peritoneal immunity and the risk of spontaneous bacterial peritonitis in cirrhosis: A combined prospective-retrospective study. Scientific Reports, 2017, 7, 4914.	3.3	11
46	Serum metabolic signatures in patients with overt hepatic encephalopathy. Journal of Hepatology, 2017, 67, 1114-1115.	3.7	0
47	Development of an advanced diagnostic concept for intestinal inflammation: molecular visualisation of nitric oxide in macrophages by functional poly(lactic-co-glycolic acid) microspheres. Beilstein Journal of Nanotechnology, 2017, 8, 1637-1641.	2.8	0
48	Cyclophosphamide Pulse Therapy in Severe Refractory Crohn's Disease: A Retrospective Multicenter Case Series. Inflammatory Intestinal Diseases, 2017, 2, 139-146.	1.9	1
49	Risk Factors for Multi-Drug Resistant Pathogens and Failure of Empiric First-Line Therapy in Acute Cholangitis. PLoS ONE, 2017, 12, e0169900.	2.5	35
50	Fecal Microbiota Transplant in Patients With Re current Clostridium Difficile Infection. Deutsches Ärzteblatt International, 2016, 113, 583-9.	0.9	35
51	Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study. Alimentary Pharmacology and Therapeutics, 2016, 44, 1199-1212.	3.7	137
52	Vedolizumab induction therapy for inflammatory bowel disease in clinical practice â€ a nationwide consecutive German cohort study. Alimentary Pharmacology and Therapeutics, 2016, 43, 1090-1102.	3.7	155
53	Motivation of patients with inflammatory bowel disease to participate in a clinical trial. Zeitschrift Fur Gastroenterologie, 2016, 54, 1123-1129.	0.5	8
54	NOD2 Risk Variants and Pathological Bacterial Translocation in Decompensated Cirrhosis. Digestive Diseases and Sciences, 2016, 61, 2142-2144.	2.3	2

#	ARTICLE	IF	CITATIONS
55	The prognostic significance of bacterial <sc>DNA</sc> in patients with decompensated cirrhosis and suspected infection. <i>Liver International</i> , 2016, 36, 1133-1142.	3.9	36
56	Azathioprine-induced Acute Pancreatitis in Patients with Inflammatory Bowel Diseasesâ€”A Prospective Study on Incidence and Severity. <i>Journal of Crohn's and Colitis</i> , 2016, 10, 61-68.	1.3	81
57	Vedolizumab for the treatment of ulcerative colitis. <i>Expert Review of Gastroenterology and Hepatology</i> , 2016, 10, 165-175.	3.0	7
58	Letter: serum vitamin D levels in primary biliary cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2015, 42, 633-634.	3.7	2
59	Patient-relevant Endpoints in Inflammatory Bowel Diseases - Have Changes Occurred in Germany over the Past Twelve Years?. <i>Journal of Crohn's and Colitis</i> , 2015, 9, 390-397.	1.3	9
60	Ferric maltol (ST10): a novel oral iron supplement for the treatment of iron deficiency anemia in inflammatory bowel disease. <i>Expert Opinion on Pharmacotherapy</i> , 2015, 16, 2859-2867.	1.8	17
61	Ferric Maltol Is Effective in Correcting Iron Deficiency Anemia in Patients with Inflammatory Bowel Disease. <i>Inflammatory Bowel Diseases</i> , 2015, 21, 579-588.	1.9	108
62	Medical Therapy of Active Ulcerative Colitis. <i>Visceral Medicine</i> , 2015, 31, 236-245.	1.3	6
63	Classification and prediction of HCC tissues by Raman imaging with identification of fatty acids as potential lipid biomarkers. <i>Journal of Cancer Research and Clinical Oncology</i> , 2015, 141, 407-418.	2.5	23
64	Morbus Crohn. , 2015, , 1-12.		0
65	Drug delivery strategies in the therapy of inflammatory bowel disease. <i>Advanced Drug Delivery Reviews</i> , 2014, 71, 58-76.	13.7	196
66	Discrimination and classification of liver cancer cells and proliferation states by Raman spectroscopic imaging. <i>Analyst, The</i> , 2014, 139, 6036-6043.	3.5	54
67	Optimising risk stratification in primary biliary cirrhosis: AST/platelet ratio index predicts outcome independent of ursodeoxycholic acid response. <i>Journal of Hepatology</i> , 2014, 60, 1249-1258.	3.7	113
68	Risk factors and outcome of bacterial infections in cirrhosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 2542.	3.3	102
69	Parameters of a severe disease course in ulcerative colitis. <i>World Journal of Gastroenterology</i> , 2014, 20, 12574.	3.3	18
70	Nano- and microscaled particles for drug targeting to inflamed intestinal mucosaâ€”A first in vivo study in human patients. <i>Journal of Controlled Release</i> , 2013, 165, 139-145.	9.9	183
71	State of the Art: Therapeutical Strategies for the Treatment of Inflammatory Bowel Disease. <i>Current Drug Therapy</i> , 2013, 8, 99-120.	0.3	3
72	Classification of inflammatory bowel diseases by means of Raman spectroscopic imaging of epithelium cells. <i>Journal of Biomedical Optics</i> , 2012, 17, 0760301.	2.6	68

#	ARTICLE	IF	CITATIONS
73	Emergence of spontaneous bacterial peritonitis due to enterococci – risk factors and outcome in a 12-year retrospective study. <i>Alimentary Pharmacology and Therapeutics</i> , 2012, 35, 1199-1208.	3.7	57
74	Predictors for subsequent need for immunosuppressive therapy in early Crohn's disease. <i>Journal of Crohn's and Colitis</i> , 2012, 6, 21-28.	1.3	16
75	<i>NOD2</i> gene variants are a risk factor for culture- positive spontaneous bacterial peritonitis and monomicrobial bacterascites in cirrhosis. <i>Liver International</i> , 2012, 32, 223-230.	3.9	59
76	Magnetic Active Agent Release System (MAARS): Evaluation of a new way for a reproducible, externally controlled drug release into the small intestine. <i>Journal of Controlled Release</i> , 2012, 161, 722-727.	9.9	25
77	Medical and surgical therapy of inflammatory bowel disease in the elderly – Prospects and complications. <i>Journal of Crohn's and Colitis</i> , 2011, 5, 177-188.	1.3	51
78	An unmet medical need: Advances in endoscopic imaging of colorectal neoplasia. <i>Journal of Biophotonics</i> , 2011, 4, 482-489.	2.3	19
79	Adverse effects of biologics used for treating IBD. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2010, 24, 167-182.	2.4	175
80	Surveillance strategies in inflammatory bowel disease. <i>Minerva Gastroenterologica E Dietologica</i> , 2010, 56, 189-201.	2.2	6
81	Drug Monitoring in Inflammatory Bowel Disease: Helpful or Dispensable?. <i>Digestive Diseases</i> , 2009, 27, 394-403.	1.9	14
82	Malignant Transformation in Inflammatory Bowel Disease – Surveillance Guide. <i>Digestive Diseases</i> , 2009, 27, 584-590.	1.9	8
83	Every slow-wave impulse is associated with motor activity of the human stomach. <i>American Journal of Physiology - Renal Physiology</i> , 2009, 296, G709-G716.	3.4	28
84	Cholestatic hepatitis, acute acalculous cholecystitis, and hemolytic anemia: primary Epstein-Barr virus infection under azathioprine. <i>Inflammatory Bowel Diseases</i> , 2009, 15, 1613-1616.	1.9	28
85	Interleukin-18 is increased only in a minority of patients with active Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2007, 22, 1013-1020.	2.2	7
86	Expression of Interleukin-12-Related Cytokine Transcripts in Inflammatory Bowel Disease: Elevated Interleukin-23p19 and Interleukin-27p28 in Crohn's Disease But Not in Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2005, 11, 16-23.	1.9	245
87	Etiology and pathogenesis of inflammatory bowel disease. <i>Minerva Gastroenterologica E Dietologica</i> , 2005, 51, 127-45.	2.2	45
88	An interleukin 12 p40-IgG2b fusion protein abrogates T cell mediated inflammation: anti-inflammatory activity in Crohn's disease and experimental colitis in vivo. <i>Gut</i> , 2004, 53, 339-345.	12.1	55
89	Biopsychosocial Determinants of Health-Related Quality of Life After Ileal Pouch Anal Anastomosis for Ulcerative Colitis*. <i>Inflammatory Bowel Diseases</i> , 2004, 10, 399-407.	1.9	29
90	Downregulation of CD44v6 in colorectal carcinomas is associated with hypermethylation of the CD44 promoter region. <i>Experimental and Molecular Pathology</i> , 2003, 74, 262-266.	2.1	11

#	ARTICLE	IF	CITATIONS
91	Safety and efficacy of intravenous pulse cyclophosphamide in acute steroid refractory inflammatory bowel disease. <i>Gut</i> , 2003, 52, 377-382.	12.1	38
92	Role of Infections in the Manifestation or Reactivation of Inflammatory Bowel Diseases. <i>Inflammatory Bowel Diseases</i> , 2002, 8, 213-218.	1.9	63
93	Increased expression of interleukin-12 receptor $\beta 2$ on lamina propria mononuclear cells of patients with active Crohn's disease. <i>International Journal of Colorectal Disease</i> , 2002, 17, 303-310.	2.2	8
94	Immune response to autologous and heterologous <i>Helicobacter pylori</i> antigens in humans. <i>Microscopy Research and Technique</i> , 2001, 53, 419-424.	2.2	8
95	Activation of $\beta 1$ integrins mediates proliferation and inhibits apoptosis of intestinal CD4-positive lymphocytes. <i>European Journal of Immunology</i> , 2001, 31, 1228-1238.	2.9	25
96	Modulation of gastrointestinal inflammation by chimeric proteins in experimental models. <i>Zeitschrift Fur Gastroenterologie</i> , 2000, 38, 647-652.	0.5	3
97	Comparable expression of matrix metalloproteinases 1 and 2 in pouchitis and ulcerative colitis. <i>Gut</i> , 2000, 47, 415-422.	12.1	91
98	Pattern of mucosal adaptation in acute and chronic pouchitis. <i>Diseases of the Colon and Rectum</i> , 1999, 42, 1311-1317.	1.3	24
99	IgG, albumin, and sCD44 in whole-gut lavage fluid are useful clinical markers for assessing the presence and activity of pouchitis. <i>International Journal of Colorectal Disease</i> , 1999, 14, 35-40.	2.2	17
100	Role of T Cells in Mucosal Transformation of Ileoanal Pouches. <i>Annals of the New York Academy of Sciences</i> , 1998, 859, 231-236.	3.8	0
101	Increased state of activation of CD4 positive T cells and elevated interferon β production in pouchitis. <i>Gut</i> , 1998, 43, 499-505.	12.1	85
102	Esophageal Involvement in Cicatricial Pemphigoid. <i>Endoscopy</i> , 1998, 30, 657-661.	1.8	13